Passage Bio Received Notice of Noncompliance
Passage Bio received a noncompliance notice from Nasdaq for failing to meet the $2.5M stockholders' equity requirement, reporting only $50,000. The company expects its pending merger with Remix Therapeutics to resolve the issue, with shares expected to trade under the symbol RMTX post-merger.
How this was made

The 30-second read
Why it matters
The filing reports a noncompliance notice tied to equity shortfall, creating a compliance and potential delisting overhang. The company’s stated expectation is that its pending merger with Remix Therapeutics will restore compliance after closing, and the shares are expected to trade under a new symbol post-close.
Market read
This is a company-specific exchange compliance risk update that can drive near-term volatility and position sizing decisions until merger closing reduces delisting concerns.
What to watch
Traders should monitor merger closing timeline, any Nasdaq cure period details not included here, and whether the company’s equity figure implies broader balance-sheet stress beyond the listing rule.
Background
Nasdaq Listing Rule 5550(b)(1) requires at least $2.5 million in stockholders' equity, with alternative requirements available if the primary threshold is not met.
Ticker impact
Passage Bio disclosed a Nasdaq Listing Rule 5550(b)(1) noncompliance notice after reporting only $50,000 stockholders' equity versus the $2.5M requirement.
Likely downward pressure or volatility as traders price delisting/compliance risk until merger closing clarity improves.
The notice itself has no immediate trading effect, but it signals potential listing risk and can affect liquidity and sentiment. The merger-based compliance plan may cushion the impact, yet timing uncertainty remains.
Market effects
Biotech microcap listing-compliance headlines can modestly raise perceived delisting risk across similar Nasdaq-listed development-stage issuers.
Primarily US microcap sentiment, with limited spillover beyond Nasdaq biotech peers.
Low, as the event is exchange-specific and not tied to global macro or cross-border fundamentals.
Counterpoint
Because the notice states it has no immediate effect and the company expects merger closing to restore compliance, the market may treat this as procedural rather than existential.
Key entities
- companyPassage Bio, Inc.
Nasdaq-listed biotech that received a noncompliance notice for insufficient stockholders' equity under Rule 5550(b)(1).
- companyRemix Therapeutics
Counterparty in Passage Bio’s pending merger expected to restore Nasdaq compliance after closing.
